Ipsen (FR:IPN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Iqirvo (elafibranor), a new treatment for primary biliary cholangitis (PBC) by Ipsen, has been approved by the European Commission, marking the first advancement in nearly a decade for this rare liver disease. The approval is based on the ELATIVE phase III trial results, which showed a significant improvement over placebo in managing disease progression and symptoms like itch. This medication is a first-in-class oral PPAR agonist, providing a new option for patients who do not respond to or cannot tolerate the current first-line therapy, UDCA.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.